{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:17:37Z","timestamp":1789579057645,"version":"build-2803163510"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00535-024-02179-8","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T10:56:53Z","timestamp":1733741813000},"page":"10-23","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Utility of Mac-2 binding protein glycosylation isomer as an excellent biomarker for the prediction of liver fibrosis, activity, and hepatocellular carcinoma onset: an expert review"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5485-902X","authenticated-orcid":false,"given":"Yoshihiro","family":"Kamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Sumida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Japan Study Group of NAFLD (JSG-NAFLD)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"key":"2179_CR1","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.cgh.2022.01.002","volume":"21","author":"H Fujii","year":"2023","unstructured":"Fujii H, Iwaki M, Hayashi H, et al. Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients: a multicenter registry-based cohort study. Clin Gastroenterol Hepatol. 2023;21:370\u20139. https:\/\/doi.org\/10.1016\/j.cgh.2022.01.002.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2179_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00535-022-01932-1","volume":"58","author":"Y Kamada","year":"2023","unstructured":"Kamada Y, Nakamura T, Isobe S, et al. SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum. J Gastroenterol. 2023;58:79\u201397. https:\/\/doi.org\/10.1007\/s00535-022-01932-1.","journal-title":"J Gastroenterol"},{"key":"2179_CR3","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/j.ultrasmedbio.2023.03.023","volume":"49","author":"H Hayashi","year":"2023","unstructured":"Hayashi H, Kamada Y, Fujii H, et al. Prediction of liver-related events with a combination of liver stiffness measurements and controlled attenuation parameters in japanese patients with biopsy-proven non-alcoholic fatty liver disease. Ultrasound Med Biol. 2023;49:1658\u201364. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2023.03.023.","journal-title":"Ultrasound Med Biol"},{"key":"2179_CR4","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/hepr.13938","volume":"53","author":"K Miura","year":"2023","unstructured":"Miura K, Hayashi H, Kamada Y, et al. Agile 3+ and Agile 4, noninvasive tests for liver fibrosis, are excellent formulae to predict liver-related events in nonalcoholic fatty liver disease. Hepatol Res. 2023;53:978\u201388. https:\/\/doi.org\/10.1111\/hepr.13938.","journal-title":"Hepatol Res"},{"key":"2179_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.11.022","author":"T Arai","year":"2023","unstructured":"Arai T, Takahashi H, Seko Y, et al. Accuracy of the enhanced liver fibrosis test in patients with type 2 diabetes mellitus and its clinical implications. Clin Gastroenterol Hepatol. 2023. https:\/\/doi.org\/10.1016\/j.cgh.2023.11.022.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2179_CR6","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.2337\/dc23-S004","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2023. Diabetes Care. 2023;46:S49-s67. https:\/\/doi.org\/10.2337\/dc23-S004.","journal-title":"Diabetes Care"},{"key":"2179_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000845","author":"RK Sterling","year":"2024","unstructured":"Sterling RK, Patel K, Duarte-Rojo A, et al. AASLD practice guideline on blood-based non-invasive liver disease assessments of hepatic fibrosis and steatosis. Hepatology. 2024. https:\/\/doi.org\/10.1097\/hep.0000000000000845.","journal-title":"Hepatology"},{"key":"2179_CR8","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/srep01065","volume":"3","author":"A Kuno","year":"2013","unstructured":"Kuno A, Ikehara Y, Tanaka Y, et al. A serum \u201csweet-doughnut\u201d protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013;3:1065. https:\/\/doi.org\/10.1038\/srep01065.","journal-title":"Sci Rep"},{"key":"2179_CR9","first-page":"3005","volume":"46","author":"S Iacobelli","year":"1986","unstructured":"Iacobelli S, Arno E, D\u2019Orazio A, et al. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res. 1986;46:3005\u201310.","journal-title":"Cancer Res"},{"key":"2179_CR10","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1023\/B:GLYC.0000014085.00706.d4","volume":"19","author":"A Grassadonia","year":"2004","unstructured":"Grassadonia A, Tinari N, Iurisci I, et al. 90K (Mac-2bp) and galectins in tumor progression and metastasis. Glycoconj J. 2004;19:551\u20136. https:\/\/doi.org\/10.1023\/B:GLYC.0000014085.00706.d4.","journal-title":"Glycoconj J"},{"key":"2179_CR11","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.bbagen.2007.05.006","volume":"1770","author":"M Przybylo","year":"2007","unstructured":"Przybylo M, Martuszewska D, Pochec E, et al. Identification of proteins bearing beta1-6 branched N-glycans in human melanoma cell lines from different progression stages by tandem mass spectrometry analysis. Biochim Biophys Acta. 2007;1770:1427\u201335. https:\/\/doi.org\/10.1016\/j.bbagen.2007.05.006.","journal-title":"Biochim Biophys Acta"},{"key":"2179_CR12","doi-asserted-by":"publisher","first-page":"14245","DOI":"10.1016\/S0021-9258(19)85233-X","volume":"268","author":"K Koths","year":"1993","unstructured":"Koths K, Taylor E, Halenbeck R, et al. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J Biol Chem. 1993;268:14245\u20139.","journal-title":"J Biol Chem"},{"key":"2179_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1022>3.0.CO;2-Z","volume":"91","author":"N Tinari","year":"2001","unstructured":"Tinari N, Kuwabara I, Huflejt ME, et al. Glycoprotein 90K\/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int J Cancer J Int Cancer. 2001;91:167\u201372.","journal-title":"Int J Cancer J Int Cancer"},{"key":"2179_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/0968-0004(94)90165-1","volume":"19","author":"D Resnick","year":"1994","unstructured":"Resnick D, Pearson A, Krieger M. The SRCR superfamily: a family reminiscent of the Ig superfamily. Trends Biochem Sci. 1994;19:5\u20138.","journal-title":"Trends Biochem Sci"},{"key":"2179_CR15","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1073\/pnas.96.6.3006","volume":"96","author":"M Trahey","year":"1999","unstructured":"Trahey M, Weissman IL. Cyclophilin C-associated protein: a normal secreted glycoprotein that down-modulates endotoxin and proinflammatory responses in vivo. Proc Natl Acad Sci USA. 1999;96:3006\u201311.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2179_CR16","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1006\/bbrc.1998.8708","volume":"246","author":"J Ochieng","year":"1998","unstructured":"Ochieng J, Leite-Browning ML, Warfield P. Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Biochem Biophys Res Commun. 1998;246:788\u201391. https:\/\/doi.org\/10.1006\/bbrc.1998.8708.","journal-title":"Biochem Biophys Res Commun"},{"key":"2179_CR17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S0168-8278(96)80076-6","volume":"25","author":"M Artini","year":"1996","unstructured":"Artini M, Natoli C, Tinari N, et al. Elevated serum levels of 90K\/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol. 1996;25:212\u20137. https:\/\/doi.org\/10.1016\/S0168-8278(96)80076-6.","journal-title":"J Hepatol"},{"key":"2179_CR18","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/j.1365-2893.2009.01083.x","volume":"16","author":"KJ Cheung","year":"2009","unstructured":"Cheung KJ, Tilleman K, Deforce D, et al. The HCV serum proteome: a search for fibrosis protein markers. J Viral Hepat. 2009;16:418\u201329. https:\/\/doi.org\/10.1111\/j.1365-2893.2009.01083.x.","journal-title":"J Viral Hepat"},{"key":"2179_CR19","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/prca.201200137","volume":"7","author":"Y Kamada","year":"2013","unstructured":"Kamada Y, Fujii H, Fujii H, et al. Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis. Proteom Clin Appl. 2013;7:648\u201356. https:\/\/doi.org\/10.1002\/prca.201200137.","journal-title":"Proteom Clin Appl"},{"key":"2179_CR20","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1002\/hep.28002","volume":"62","author":"Y Kamada","year":"2015","unstructured":"Kamada Y, Ono M, Hyogo H, et al. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers. Hepatology. 2015;62:1433\u201343. https:\/\/doi.org\/10.1002\/hep.28002.","journal-title":"Hepatology"},{"key":"2179_CR21","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/hep.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966\u201386. https:\/\/doi.org\/10.1097\/hep.0000000000000520.","journal-title":"Hepatology"},{"key":"2179_CR22","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","volume":"80","author":"H Hagstr\u00f6m","year":"2024","unstructured":"Hagstr\u00f6m H, Vessby J, Ekstedt M, et al. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2024;80:e76\u20137. https:\/\/doi.org\/10.1016\/j.jhep.2023.08.026.","journal-title":"J Hepatol"},{"key":"2179_CR23","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.jhep.2024.01.014","volume":"80","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Paik JM, Stepanova M, et al. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J Hepatol. 2024;80:694\u2013701. https:\/\/doi.org\/10.1016\/j.jhep.2024.01.014.","journal-title":"J Hepatol"},{"issue":"8","key":"2179_CR24","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.gastha.2024.08.006","volume":"3","author":"Y Kamada","year":"2024","unstructured":"Kamada Y, Fujii H, Suzuki Y, et al. Clinical characteristics of steatotic liver disease categories in a large cohort of Japanese health checkup participants. Gastro Hep Adv. 2024;3(8):1148\u201356.","journal-title":"Gastro Hep Adv"},{"key":"2179_CR25","doi-asserted-by":"publisher","first-page":"24085","DOI":"10.1074\/jbc.M116.750463","volume":"291","author":"O Haji-Ghassemi","year":"2016","unstructured":"Haji-Ghassemi O, Gilbert M, Spence J, et al. Molecular basis for recognition of the cancer glycobiomarker, LacdiNAc (GalNAc[beta1\u2013>4]GlcNAc), by Wisteria floribunda Agglutinin. J Biol Chem. 2016;291:24085\u201395. https:\/\/doi.org\/10.1074\/jbc.M116.750463.","journal-title":"J Biol Chem"},{"key":"2179_CR26","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1007\/s00535-023-02043-1","volume":"58","author":"H Uojima","year":"2023","unstructured":"Uojima H, Nakabayashi K, Yamasaki K, et al. New chemiluminescent enzyme immunoassay for quantitative measurement of Mac-2 binding protein glycosylation isomer in chronic liver disease. J Gastroenterol. 2023;58:1252\u201360. https:\/\/doi.org\/10.1007\/s00535-023-02043-1.","journal-title":"J Gastroenterol"},{"key":"2179_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010040","author":"N Tamaki","year":"2020","unstructured":"Tamaki N, Kurosaki M, Takahashi Y, et al. Wisteria floribunda agglutinin-positive mac-2 binding protein as a screening tool for significant liver fibrosis in health checkup. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms22010040.","journal-title":"Int J Mol Sci"},{"key":"2179_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10080579","author":"Y Sumida","year":"2020","unstructured":"Sumida Y, Yoneda M, Seko Y, et al. Surveillance of hepatocellular carcinoma in nonalcoholic fatty liver disease. Diagnostics (Basel). 2020. https:\/\/doi.org\/10.3390\/diagnostics10080579.","journal-title":"Diagnostics (Basel)"},{"key":"2179_CR29","doi-asserted-by":"publisher","first-page":"220","DOI":"10.4254\/wjh.v12.i5.220","volume":"12","author":"TTT Pham","year":"2020","unstructured":"Pham TTT, Ho DT, Nguyen T. Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population. World J Hepatol. 2020;12:220\u20139. https:\/\/doi.org\/10.4254\/wjh.v12.i5.220.","journal-title":"World J Hepatol"},{"key":"2179_CR30","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1586\/14789450.2015.1084874","volume":"12","author":"H Narimatsu","year":"2015","unstructured":"Narimatsu H. Development of M2BPGi: a novel fibrosis serum glyco-biomarker for chronic hepatitis\/cirrhosis diagnostics. Expert Rev Proteom. 2015;12:683\u201393. https:\/\/doi.org\/10.1586\/14789450.2015.1084874.","journal-title":"Expert Rev Proteom"},{"key":"2179_CR31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/hepr.13459","volume":"50","author":"E Miyoshi","year":"2020","unstructured":"Miyoshi E, Kamada Y, Suzuki T. Functional glycomics: application to medical science and hepatology. Hepatol Res. 2020;50:153\u201364. https:\/\/doi.org\/10.1111\/hepr.13459.","journal-title":"Hepatol Res"},{"key":"2179_CR32","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/jgh.13708","volume":"32","author":"Y Bekki","year":"2017","unstructured":"Bekki Y, Yoshizumi T, Shimoda S, et al. Hepatic stellate cells secreting WFA(+)-M2BP: Its role in biological interactions with Kupffer cells. J Gastroenterol Hepatol. 2017;32:1387\u201393. https:\/\/doi.org\/10.1111\/jgh.13708.","journal-title":"J Gastroenterol Hepatol"},{"key":"2179_CR33","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00535-017-1425-z","volume":"53","author":"K Shirabe","year":"2018","unstructured":"Shirabe K, Bekki Y, Gantumur D, et al. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis. J Gastroenterol. 2018;53:819\u201326. https:\/\/doi.org\/10.1007\/s00535-017-1425-z.","journal-title":"J Gastroenterol"},{"key":"2179_CR34","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1111\/hepr.13648","volume":"51","author":"D Gantumur","year":"2021","unstructured":"Gantumur D, Harimoto N, Muranushi R, et al. Hepatic stellate cell as a Mac-2-binding protein-producing cell in patients with liver fibrosis. Hepatol Res. 2021;51:1058\u201363. https:\/\/doi.org\/10.1111\/hepr.13648.","journal-title":"Hepatol Res"},{"key":"2179_CR35","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/hep4.1080","volume":"1","author":"Y Kamada","year":"2017","unstructured":"Kamada Y, Ono M, Hyogo H, et al. Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis. Hepatol Commun. 2017;1:780\u201391. https:\/\/doi.org\/10.1002\/hep4.1080.","journal-title":"Hepatol Commun"},{"key":"2179_CR36","doi-asserted-by":"publisher","first-page":"22403","DOI":"10.1074\/jbc.M110.215301","volume":"286","author":"M Nonaka","year":"2011","unstructured":"Nonaka M, Ma BY, Imaeda H, et al. Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) recognizes a novel ligand, Mac-2-binding protein, characteristically expressed on human colorectal carcinomas. J Biol Chem. 2011;286:22403\u201313. https:\/\/doi.org\/10.1074\/jbc.M110.215301.","journal-title":"J Biol Chem"},{"key":"2179_CR37","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/jb\/mvad015","volume":"173","author":"M Masuda","year":"2023","unstructured":"Masuda M, Asuka T, Terao N, et al. Establishment of a novel 70K Mac-2 binding protein antibody through screening of fucosylation-related antibodies. J Biochem. 2023;173:487\u201395. https:\/\/doi.org\/10.1093\/jb\/mvad015.","journal-title":"J Biochem"},{"key":"2179_CR38","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/hepr.12819","volume":"47","author":"A Iwata","year":"2017","unstructured":"Iwata A, Kamada Y, Ebisutani Y, et al. Establishment of mouse Mac-2 binding protein enzyme-linked immunosorbent assay and its application for mouse chronic liver disease models. Hepatol Res. 2017;47:902\u20139. https:\/\/doi.org\/10.1111\/hepr.12819.","journal-title":"Hepatol Res"},{"key":"2179_CR39","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1021\/pr201154k","volume":"11","author":"T Nakagawa","year":"2012","unstructured":"Nakagawa T, Moriwaki K, Terao N, et al. Analysis of polarized secretion of fucosylated alpha-fetoprotein in HepG2 cells. J Proteome Res. 2012;11:2798\u2013806. https:\/\/doi.org\/10.1021\/pr201154k.","journal-title":"J Proteome Res"},{"key":"2179_CR40","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/cas.16087","volume":"115","author":"T Yamanaka","year":"2024","unstructured":"Yamanaka T, Araki K, Yokobori T, et al. Potential of Mac-2-binding protein glycan isomer as a new therapeutic target in pancreatic cancer. Cancer Sci. 2024;115:1241\u20139. https:\/\/doi.org\/10.1111\/cas.16087.","journal-title":"Cancer Sci"},{"key":"2179_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13802","author":"K Ito","year":"2017","unstructured":"Ito K, Murotani K, Nakade Y, et al. Serum WFA+ -M2BP levels predict liver fibrosis, development of hepatocellular carcinoma, and overall survival: a meta-analysis. J Gastroenterol Hepatol. 2017. https:\/\/doi.org\/10.1111\/jgh.13802.","journal-title":"J Gastroenterol Hepatol"},{"key":"2179_CR42","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s00535-014-1007-2","volume":"50","author":"M Abe","year":"2015","unstructured":"Abe M, Miyake T, Kuno A, et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol. 2015;50:776\u201384. https:\/\/doi.org\/10.1007\/s00535-014-1007-2.","journal-title":"J Gastroenterol"},{"key":"2179_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/liv.13188","volume":"37","author":"X Zou","year":"2017","unstructured":"Zou X, Zhu MY, Yu DM, et al. Serum WFA+ -M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection. Liver Int. 2017;37:35\u201344. https:\/\/doi.org\/10.1111\/liv.13188.","journal-title":"Liver Int"},{"key":"2179_CR44","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/hepr.12595","volume":"46","author":"H Nishikawa","year":"2016","unstructured":"Nishikawa H, Enomoto H, Iwata Y, et al. Impact of serum Wisteria floribunda agglutinin positive Mac-2-binding protein and serum interferon-\u03b3-inducible protein-10 in primary biliary cirrhosis. Hepatol Res. 2016;46:575\u201383. https:\/\/doi.org\/10.1111\/hepr.12595.","journal-title":"Hepatol Res"},{"key":"2179_CR45","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/hepr.12596","volume":"46","author":"H Nishikawa","year":"2016","unstructured":"Nishikawa H, Enomoto H, Iwata Y, et al. Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis. Hepatol Res. 2016;46:613\u201321. https:\/\/doi.org\/10.1111\/hepr.12596.","journal-title":"Hepatol Res"},{"key":"2179_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12112650","author":"CH Liu","year":"2022","unstructured":"Liu CH, Liu CJ, Su TH, et al. Serum Mac-2 binding protein glycosylation isomer to predict the severity of hepatic fibrosis in patients with hepatitis C virus infection. Diagnostics (Basel). 2022. https:\/\/doi.org\/10.3390\/diagnostics12112650.","journal-title":"Diagnostics (Basel)"},{"key":"2179_CR47","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1002\/hep.27305","volume":"60","author":"K Yamasaki","year":"2014","unstructured":"Yamasaki K, Tateyama M, Abiru S, et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology. 2014;60:1563\u201370. https:\/\/doi.org\/10.1002\/hep.27305.","journal-title":"Hepatology"},{"key":"2179_CR48","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1007\/s12072-016-9754-1","volume":"10","author":"H Nagata","year":"2016","unstructured":"Nagata H, Nakagawa M, Nishimura-Sakurai Y, et al. Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy. Hepatol Int. 2016;10:956\u201364. https:\/\/doi.org\/10.1007\/s12072-016-9754-1.","journal-title":"Hepatol Int"},{"key":"2179_CR49","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1007\/s00535-020-01715-6","volume":"55","author":"M Nakagawa","year":"2020","unstructured":"Nakagawa M, Nawa N, Takeichi E, et al. Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs. J Gastroenterol. 2020;55:990\u20139. https:\/\/doi.org\/10.1007\/s00535-020-01715-6.","journal-title":"J Gastroenterol"},{"key":"2179_CR50","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16680","author":"YP Chang","year":"2024","unstructured":"Chang YP, Liu CH, Huang CB, et al. Serum Mac-2 binding protein glycosylation isomer dynamics in patients achieving sustained virologic response for hepatitis C virus. J Gastroenterol Hepatol. 2024. https:\/\/doi.org\/10.1111\/jgh.16680.","journal-title":"J Gastroenterol Hepatol"},{"key":"2179_CR51","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/hep4.1941","volume":"6","author":"K Kawata","year":"2022","unstructured":"Kawata K, Atsukawa M, Ohta K, et al. Mac-2-binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C. Hepatol Commun. 2022;6:1855\u201369. https:\/\/doi.org\/10.1002\/hep4.1941.","journal-title":"Hepatol Commun"},{"key":"2179_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129053","volume":"10","author":"R Sasaki","year":"2015","unstructured":"Sasaki R, Yamasaki K, Abiru S, et al. Serum Wisteria floribunda agglutinin-positive mac-2 binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis C after sustained virological response. PLoS ONE. 2015;10: e0129053. https:\/\/doi.org\/10.1371\/journal.pone.0129053.","journal-title":"PLoS ONE"},{"key":"2179_CR53","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01463-18","author":"N Akuta","year":"2019","unstructured":"Akuta N, Suzuki F, Sezaki H, et al. Complex association of virus- and host-related factors with hepatocellular carcinoma rate following hepatitis C virus clearance. J Clin Microbiol. 2019. https:\/\/doi.org\/10.1128\/jcm.01463-18.","journal-title":"J Clin Microbiol"},{"key":"2179_CR54","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1002\/hep4.1934","volume":"6","author":"Y Kamada","year":"2022","unstructured":"Kamada Y, Nakahara T, Munekage K, et al. Serum Mac-2 binding protein level predicts the development of liver-related events and colorectal cancer in patients with NAFLD. Hepatol Commun. 2022;6:1527\u201336. https:\/\/doi.org\/10.1002\/hep4.1934.","journal-title":"Hepatol Commun"},{"key":"2179_CR55","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1111\/jvh.12575","volume":"23","author":"H Nishikawa","year":"2016","unstructured":"Nishikawa H, Enomoto H, Iwata Y, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study. J Viral Hepat. 2016;23:977\u201384. https:\/\/doi.org\/10.1111\/jvh.12575.","journal-title":"J Viral Hepat"},{"key":"2179_CR56","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/hepr.12703","volume":"47","author":"A Ishii","year":"2017","unstructured":"Ishii A, Nishikawa H, Enomoto H, et al. Clinical implications of serum Wisteria floribunda agglutinin-positive Mac-2-binding protein in treatment-na\u00efve chronic hepatitis B. Hepatol Res. 2017;47:204\u201315. https:\/\/doi.org\/10.1111\/hepr.12703.","journal-title":"Hepatol Res"},{"key":"2179_CR57","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/hepr.12712","volume":"47","author":"Y Ichikawa","year":"2017","unstructured":"Ichikawa Y, Joshita S, Umemura T, et al. Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Hepatol Res. 2017;47:226\u201333. https:\/\/doi.org\/10.1111\/hepr.12712.","journal-title":"Hepatol Res"},{"key":"2179_CR58","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/liv.13341","volume":"37","author":"SU Kim","year":"2017","unstructured":"Kim SU, Heo JY, Kim BK, et al. Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development. Liver Int. 2017;37:879\u201387. https:\/\/doi.org\/10.1111\/liv.13341.","journal-title":"Liver Int"},{"key":"2179_CR59","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000504650","volume":"9","author":"TC Tseng","year":"2020","unstructured":"Tseng TC, Peng CY, Hsu YC, et al. Baseline Mac-2 binding protein glycosylation isomer level stratifies risks of hepatocellular carcinoma in chronic hepatitis B patients with oral antiviral therapy. Liver Cancer. 2020;9:207\u201320. https:\/\/doi.org\/10.1159\/000504650.","journal-title":"Liver Cancer"},{"key":"2179_CR60","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.62347\/dagb7277","volume":"14","author":"CH Chen","year":"2024","unstructured":"Chen CH, Wang JH, Lai HC, et al. Mac-2 binding protein glycosylation isomer at 5 years of antiviral therapy predict hepatocellular carcinoma and mortality beyond year 5 in chronic hepatitis B patients with cirrhosis. Am J Cancer Res. 2024;14:2465\u201377. https:\/\/doi.org\/10.62347\/dagb7277.","journal-title":"Am J Cancer Res"},{"key":"2179_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261878","volume":"16","author":"T Suzuki","year":"2021","unstructured":"Suzuki T, Matsuura K, Nagura Y, et al. Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection. PLoS ONE. 2021;16: e0261878. https:\/\/doi.org\/10.1371\/journal.pone.0261878.","journal-title":"PLoS ONE"},{"key":"2179_CR62","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000003328","volume":"95","author":"JY Heo","year":"2016","unstructured":"Heo JY, Kim SU, Kim BK, et al. Use of Wisteria floribunda agglutinin-positive human Mac-2 binding protein in assessing risk of hepatocellular carcinoma due to hepatitis B virus. Medicine (Baltimore). 2016;95: e3328. https:\/\/doi.org\/10.1097\/md.0000000000003328.","journal-title":"Medicine (Baltimore)"},{"key":"2179_CR63","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1111\/jgh.14637","volume":"34","author":"LY Mak","year":"2019","unstructured":"Mak LY, Ko M, To E, et al. Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients. J Gastroenterol Hepatol. 2019;34:1817\u201323. https:\/\/doi.org\/10.1111\/jgh.14637.","journal-title":"J Gastroenterol Hepatol"},{"key":"2179_CR64","doi-asserted-by":"publisher","first-page":"47507","DOI":"10.18632\/oncotarget.17670","volume":"8","author":"KS Cheung","year":"2017","unstructured":"Cheung KS, Seto WK, Wong DK, et al. Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment. Oncotarget. 2017;8:47507\u201317. https:\/\/doi.org\/10.18632\/oncotarget.17670.","journal-title":"Oncotarget"},{"key":"2179_CR65","doi-asserted-by":"publisher","first-page":"6635625","DOI":"10.1155\/2024\/6635625","volume":"2024","author":"LK Pramono","year":"2024","unstructured":"Pramono LK, Tjandrawati A, Turbawaty DK, et al. Macrophage-2-binding protein glycosylation isomer (M2BPGi) and AGAP score as markers of noninvasive test for liver fibrosis versus fibroscan in chronic hepatitis B patients: a retrospective observational study. Int J Hepatol. 2024;2024:6635625. https:\/\/doi.org\/10.1155\/2024\/6635625.","journal-title":"Int J Hepatol"},{"key":"2179_CR66","doi-asserted-by":"publisher","first-page":"04076","DOI":"10.7189\/jogh.12.04076","volume":"12","author":"JP Vincent","year":"2022","unstructured":"Vincent JP, Ndow G, Ogawa S, et al. Mac-2 binding protein glycosylation isomer (M2BPGi) to evaluate liver fibrosis and cancer in HBV-infected patients in West Africa. J Glob Health. 2022;12:04076. https:\/\/doi.org\/10.7189\/jogh.12.04076.","journal-title":"J Glob Health"},{"key":"2179_CR67","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3343\/alm.2021.41.3.302","volume":"41","author":"SY Jang","year":"2021","unstructured":"Jang SY, Tak WY, Park SY, et al. Diagnostic efficacy of serum Mac-2 binding protein glycosylation isomer and other markers for liver fibrosis in non-alcoholic fatty liver diseases. Ann Lab Med. 2021;41:302\u20139. https:\/\/doi.org\/10.3343\/alm.2021.41.3.302.","journal-title":"Ann Lab Med"},{"key":"2179_CR68","doi-asserted-by":"publisher","first-page":"10109","DOI":"10.1038\/s41598-019-46172-1","volume":"9","author":"N Tamaki","year":"2019","unstructured":"Tamaki N, Higuchi M, Kurosaki M, et al. Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease. Sci Rep. 2019;9:10109. https:\/\/doi.org\/10.1038\/s41598-019-46172-1.","journal-title":"Sci Rep"},{"key":"2179_CR69","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/hepr.12662","volume":"46","author":"H Nishikawa","year":"2016","unstructured":"Nishikawa H, Enomoto H, Iwata Y, et al. Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level in non-alcoholic steatohepatitis. Hepatol Res. 2016;46:1194\u2013202. https:\/\/doi.org\/10.1111\/hepr.12662.","journal-title":"Hepatol Res"},{"key":"2179_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277380","volume":"17","author":"I Kiyoaki","year":"2022","unstructured":"Kiyoaki I, Sumida Y, Nakade Y, et al. Mac-2 binding protein glycosylation isomer, the FIB-4 index, and a combination of the two as predictors of non-alcoholic steatohepatitis. PLoS ONE. 2022;17: e0277380. https:\/\/doi.org\/10.1371\/journal.pone.0277380.","journal-title":"PLoS ONE"},{"key":"2179_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9041119","author":"M Kim","year":"2020","unstructured":"Kim M, Jun DW, Park H, et al. Sequential combination of FIB-4 followed by M2BPGi enhanced diagnostic performance for advanced hepatic fibrosis in an average risk population. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9041119.","journal-title":"J Clin Med"},{"key":"2179_CR72","doi-asserted-by":"publisher","first-page":"283","DOI":"10.5009\/gnl230128","volume":"18","author":"SY Moon","year":"2024","unstructured":"Moon SY, Baek YH, Jang SY, et al. Proposal of a novel serological algorithm combining FIB-4 and serum M2BPGi for advanced fibrosis in nonalcoholic fatty liver disease. Gut Liver. 2024;18:283\u201393. https:\/\/doi.org\/10.5009\/gnl230128.","journal-title":"Gut Liver"},{"key":"2179_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17091545","author":"R Shigefuku","year":"2016","unstructured":"Shigefuku R, Takahashi H, Nakano H, et al. Correlations of hepatic hemodynamics, liver function, and fibrosis markers in nonalcoholic fatty liver disease: comparison with chronic hepatitis related to hepatitis C virus. Int J Mol Sci. 2016. https:\/\/doi.org\/10.3390\/ijms17091545.","journal-title":"Int J Mol Sci"},{"key":"2179_CR74","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43:1317\u201325. https:\/\/doi.org\/10.1002\/hep.21178.","journal-title":"Hepatology"},{"key":"2179_CR75","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","volume":"7","author":"AG Shah","year":"2009","unstructured":"Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1104\u201312. https:\/\/doi.org\/10.1016\/j.cgh.2009.05.033.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2179_CR76","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"CP Panel","year":"2021","unstructured":"Panel CP, Berzigotti A, Tsochatzis E, Boursier J, Castera L, Cazzagon N, Friedrich-Rust M, Petta S, Thiele M, European Association for the Study of the Liver. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis: 2021 update. J Hepatol. 2021;75:659\u201389. https:\/\/doi.org\/10.1016\/j.jhep.2021.05.025.","journal-title":"J Hepatol"},{"key":"2179_CR77","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328\u201357. https:\/\/doi.org\/10.1002\/hep.29367.","journal-title":"Hepatology"},{"key":"2179_CR78","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00535-021-01796-x","volume":"56","author":"K Tokushige","year":"2021","unstructured":"Tokushige K, Ikejima K, Ono M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020. J Gastroenterol. 2021;56:951\u201363. https:\/\/doi.org\/10.1007\/s00535-021-01796-x.","journal-title":"J Gastroenterol"},{"key":"2179_CR79","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/hepr.13054","volume":"48","author":"M Kawanaka","year":"2018","unstructured":"Kawanaka M, Tomiyama Y, Hyogo H, et al. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. Hepatol Res. 2018;48:521\u20138. https:\/\/doi.org\/10.1111\/hepr.13054.","journal-title":"Hepatol Res"},{"key":"2179_CR80","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00535-019-01551-3","volume":"54","author":"M Kanno","year":"2019","unstructured":"Kanno M, Kawaguchi K, Honda M, et al. Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis. J Gastroenterol. 2019;54:549\u201357. https:\/\/doi.org\/10.1007\/s00535-019-01551-3.","journal-title":"J Gastroenterol"},{"key":"2179_CR81","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/ajg.2015.118","volume":"110","author":"T Umemura","year":"2015","unstructured":"Umemura T, Joshita S, Sekiguchi T, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis. Am J Gastroenterol. 2015;110:857\u201364. https:\/\/doi.org\/10.1038\/ajg.2015.118.","journal-title":"Am J Gastroenterol"},{"key":"2179_CR82","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/hepr.12473","volume":"45","author":"T Hanai","year":"2015","unstructured":"Hanai T, Shiraki M, Ohnishi S, et al. Impact of serum glycosylated Wisteria floribunda agglutinin positive Mac-2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis. Hepatol Res. 2015;45:1083\u201390. https:\/\/doi.org\/10.1111\/hepr.12473.","journal-title":"Hepatol Res"},{"key":"2179_CR83","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/liv.12907","volume":"36","author":"H Toyoda","year":"2016","unstructured":"Toyoda H, Kumada T, Tada T, et al. Serum WFA+ -M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection. Liver Int. 2016;36:293\u2013301. https:\/\/doi.org\/10.1111\/liv.12907.","journal-title":"Liver Int"},{"key":"2179_CR84","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1007\/s00535-015-1063-2","volume":"50","author":"M Fujiyoshi","year":"2015","unstructured":"Fujiyoshi M, Kuno A, Gotoh M, et al. Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma. J Gastroenterol. 2015;50:1134\u201344. https:\/\/doi.org\/10.1007\/s00535-015-1063-2.","journal-title":"J Gastroenterol"},{"key":"2179_CR85","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-024-02885-z","author":"K Yugawa","year":"2024","unstructured":"Yugawa K, Maeda T, Tsuji K, et al. Mac-2 binding protein glycosylation isomer as a novel predictor of early recurrence after resection for hepatocellular carcinoma. Surg Today. 2024. https:\/\/doi.org\/10.1007\/s00595-024-02885-z.","journal-title":"Surg Today"},{"key":"2179_CR86","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/ags3.12271","volume":"3","author":"D Imai","year":"2019","unstructured":"Imai D, Maeda T, Wang H, et al. Elevation of Mac-2 binding protein glycosylation isomer after hepatectomy is associated with post-hepatectomy liver failure, total Pringle time, and renal dysfunction. Ann Gastroenterol Surg. 2019;3:515\u201322. https:\/\/doi.org\/10.1002\/ags3.12271.","journal-title":"Ann Gastroenterol Surg"},{"key":"2179_CR87","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s12185-016-2033-z","volume":"104","author":"H Totani","year":"2016","unstructured":"Totani H, Kusumoto S, Tanaka Y, et al. The value of serum Wisteria floribunda agglutinin-positive human Mac-2-binding protein as a predictive marker for hepatitis C virus-related complications after systemic chemotherapy. Int J Hematol. 2016;104:384\u201391. https:\/\/doi.org\/10.1007\/s12185-016-2033-z.","journal-title":"Int J Hematol"},{"key":"2179_CR88","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/hepr.13412","volume":"49","author":"N Ishii","year":"2019","unstructured":"Ishii N, Harimoto N, Araki K, et al. Preoperative Mac-2 binding protein glycosylation isomer level predicts postoperative ascites in patients with hepatic resection for hepatocellular carcinoma. Hepatol Res. 2019;49:1398\u2013405. https:\/\/doi.org\/10.1111\/hepr.13412.","journal-title":"Hepatol Res"},{"key":"2179_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030405","author":"Y Eso","year":"2019","unstructured":"Eso Y, Takai A, Takahashi K, et al. Combination of Mac-2 binding protein glycosylation isomer and up-to-seven criteria as a useful predictor for child-pugh grade deterioration after transarterial chemoembolization for hepatocellular carcinoma. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11030405.","journal-title":"Cancers (Basel)"},{"key":"2179_CR90","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1111\/jgh.15553","volume":"36","author":"KY Tak","year":"2021","unstructured":"Tak KY, Jang B, Lee SK, et al. Use of M2BPGi in HCC patients with TACE. J Gastroenterol Hepatol. 2021;36:2917\u201324. https:\/\/doi.org\/10.1111\/jgh.15553.","journal-title":"J Gastroenterol Hepatol"},{"key":"2179_CR91","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1007\/s00464-022-09664-2","volume":"37","author":"T Fuji","year":"2023","unstructured":"Fuji T, Kojima T, Kajioka H, et al. The preoperative M2BPGi score predicts operative difficulty and the incidence of postoperative complications in laparoscopic liver resection. Surg Endosc. 2023;37:1262\u201373. https:\/\/doi.org\/10.1007\/s00464-022-09664-2.","journal-title":"Surg Endosc"},{"key":"2179_CR92","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/lt.25870","volume":"27","author":"Y Kimura","year":"2021","unstructured":"Kimura Y, Taura K, Hai Nam N, et al. Utility of Mac-2 binding protein glycosylation isomer to evaluate graft status after liver transplantation. Liver Transpl. 2021;27:403\u201315. https:\/\/doi.org\/10.1002\/lt.25870.","journal-title":"Liver Transpl"},{"key":"2179_CR93","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.rmed.2016.04.013","volume":"115","author":"M Kono","year":"2016","unstructured":"Kono M, Nakamura Y, Oyama Y, et al. Increased levels of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in idiopathic pulmonary fibrosis. Respir Med. 2016;115:46\u201352. https:\/\/doi.org\/10.1016\/j.rmed.2016.04.013.","journal-title":"Respir Med"},{"key":"2179_CR94","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1038\/s41598-024-52969-6","volume":"14","author":"M Takeda","year":"2024","unstructured":"Takeda M, Takei H, Suzuki M, et al. Bile acid profiles in adult patients with biliary atresia who achieve native liver survival after portoenterostomy. Sci Rep. 2024;14:2492. https:\/\/doi.org\/10.1038\/s41598-024-52969-6.","journal-title":"Sci Rep"},{"key":"2179_CR95","doi-asserted-by":"publisher","first-page":"1385654","DOI":"10.3389\/fimmu.2024.1385654","volume":"15","author":"S Yoshida","year":"2024","unstructured":"Yoshida S, Koga T, Fujita Y, et al. Serum Mac-2 binding protein glycosylation isomer and galectin-3 levels in adult-onset Still\u2019s disease and their association with cytokines. Front Immunol. 2024;15:1385654. https:\/\/doi.org\/10.3389\/fimmu.2024.1385654.","journal-title":"Front Immunol"},{"key":"2179_CR96","doi-asserted-by":"publisher","first-page":"e425","DOI":"10.1210\/clinem\/dgad011","volume":"108","author":"M Higashioka","year":"2023","unstructured":"Higashioka M, Hirakawa Y, Hata J, et al. Serum Mac-2 binding protein glycosylation isomer concentrations are associated with incidence of type 2 diabetes. J Clin Endocrinol Metab. 2023;108:e425\u201333. https:\/\/doi.org\/10.1210\/clinem\/dgad011.","journal-title":"J Clin Endocrinol Metab"},{"key":"2179_CR97","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001015","author":"DQ Huang","year":"2024","unstructured":"Huang DQ, Wilson LA, Behling C, et al. Liver stiffness progression in biopsy-proven metabolic dysfunction-associated steatotic disease among people with diabetes versus people without diabetes: a prospective multicenter study. Hepatology. 2024. https:\/\/doi.org\/10.1097\/hep.0000000000001015.","journal-title":"Hepatology"},{"key":"2179_CR98","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.2337\/dc22-2048","volume":"46","author":"L Castera","year":"2023","unstructured":"Castera L, Laouenan C, Vallet-Pichard A, et al. High prevalence of NASH and advanced fibrosis in type 2 diabetes: a prospective study of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold. Diabetes Care. 2023;46:1354\u201362. https:\/\/doi.org\/10.2337\/dc22-2048.","journal-title":"Diabetes Care"},{"key":"2179_CR99","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.21037\/atm-20-5216","volume":"8","author":"H Park","year":"2020","unstructured":"Park H, Jun DW, Park HK, et al. Clinical implications of serum Mac-2-binding protein glycan isomer as a novel biomarker of advanced hepatic fibrosis in diabetes. Ann Transl Med. 2020;8:1583. https:\/\/doi.org\/10.21037\/atm-20-5216.","journal-title":"Ann Transl Med"},{"key":"2179_CR100","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001189","author":"Y Hashimoto","year":"2020","unstructured":"Hashimoto Y, Hamaguchi M, Kaji A, et al. Serum levels of mac-2 binding protein are associated with diabetic microangiopathy and macroangiopathy in people with type 2 diabetes. BMJ Open Diabetes Res Care. 2020. https:\/\/doi.org\/10.1136\/bmjdrc-2020-001189.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2179_CR101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0298151","volume":"19","author":"EH Nah","year":"2024","unstructured":"Nah EH, Choi YJ, Cho S, et al. Changes in nonalcoholic fatty liver disease and M2BPGi due to lifestyle intervention in primary healthcare. PLoS ONE. 2024;19: e0298151. https:\/\/doi.org\/10.1371\/journal.pone.0298151.","journal-title":"PLoS ONE"},{"key":"2179_CR102","doi-asserted-by":"publisher","first-page":"566","DOI":"10.21037\/atm-20-7219","volume":"9","author":"H Park","year":"2021","unstructured":"Park H, Jun DW, Park HK, et al. New sequential algorithm using Mac-2 binding protein glycosylation isomer to detect advanced carotid artery atherosclerosis. Ann Transl Med. 2021;9:566. https:\/\/doi.org\/10.21037\/atm-20-7219.","journal-title":"Ann Transl Med"},{"key":"2179_CR103","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/jgh.16154","volume":"38","author":"Y Suzuki","year":"2023","unstructured":"Suzuki Y, Maekawa S, Yamashita K, et al. Effect of a combination of pemafibrate and a mild low-carbohydrate diet on obese and non-obese patients with metabolic-associated fatty liver disease. J Gastroenterol Hepatol. 2023;38:921\u20139. https:\/\/doi.org\/10.1111\/jgh.16154.","journal-title":"J Gastroenterol Hepatol"},{"key":"2179_CR104","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare9050523","author":"H Tamai","year":"2021","unstructured":"Tamai H, Okamura J, Ohoshi T, et al. Measurements of serum Mac-2-binding protein glycosylation isomer and shear wave velocity in health checkups are useful in screening for non-alcoholic steatohepatitis. Healthcare (Basel). 2021. https:\/\/doi.org\/10.3390\/healthcare9050523.","journal-title":"Healthcare (Basel)"},{"key":"2179_CR105","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s00535-024-02100-3","volume":"59","author":"H Uojima","year":"2024","unstructured":"Uojima H, Yamasaki K, Sugiyama M, et al. Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation. J Gastroenterol. 2024;59:598\u2013608. https:\/\/doi.org\/10.1007\/s00535-024-02100-3.","journal-title":"J Gastroenterol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-024-02179-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-024-02179-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-024-02179-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T13:04:52Z","timestamp":1736427892000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-024-02179-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":105,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["2179"],"URL":"https:\/\/doi.org\/10.1007\/s00535-024-02179-8","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,9]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}